Cy­to­ki­net­ic­s' lat­est PhI­II study of ome­cam­tiv flops — kick­ing out an­oth­er leg from un­der the mar­ket case it was build­ing

Cy­to­ki­net­ics’ re­lent­less quest to demon­strate that its heart drug ome­cam­tiv has re­al val­ue ran in­to an­oth­er thick­et of bad da­ta Tues­day morn­ing.

The biotech re­port­ed that its Phase III ME­TE­ORIC study had flat failed to demon­strate an im­proved per­for­mance in ex­er­cise ca­pac­i­ty among pa­tients suf­fer­ing heart fail­ure with re­duced ejec­tion frac­tion when com­pared to a sug­ar pill.

And there was no mis­in­ter­pret­ing the bot­tom line, fo­cus­ing on pa­tients fac­ing the con­se­quences of low lev­els of oxy­gen in their tis­sue:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER